rhuMAb-E25 humanized monoclonal antibody against IgE: Update

The decision to move forward with E25 was based on results of a randomized, double-blind, placebo-controlled Phase II

Read the full 182 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE